Developer docs
API playgroundTry for free, no card

Search company profiles

Ability Pharmaceuticals

Full company profile

uuid0000c94

Namestring
Ability Pharmaceuticals
Legal namestring
ABILITY PHARMACEUTICALS, SA
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Ability Pharmaceuticals (AbilityPharma / ABILITY PHARMACEUTICALS, SA) is a clinical-stage biopharmaceutical company headquartered in Cerdanyola del Vallès (Barcelona), Catalonia, Spain, founded in 2012. It is developing a portfolio of first-in-class small-molecule anticancer drugs that induce cytotoxic autophagy selectively in cancer cells; its lead candidate ABTL0812 (WHO International Nonproprietary Name: IBRILATAZAR) is an oral compound that binds the nuclear receptors PPARα and PPARγ, induces Endoplasmic Reticular Stress, and blocks Akt activation in the PI3K/Akt/mTOR pathway, also converting "cold" tumors into immunogenic "hot" tumors. The asset has Orphan Drug Designations from both the US FDA and the European EMA for pancreatic cancer, biliary cancer, and pediatric neuroblastoma, and is currently in a Phase 2b double-blind placebo-controlled trial in 140 patients with metastatic pancreatic cancer across Spain, USA, France, and Israel, having previously reported positive Phase 2a results in endometrial cancer and squamous non-small cell lung cancer.

The company does not sell commercial products. Its revenue model is out-licensing: AbilityPharma develops drugs to late clinical stage and then licenses territorial or global rights to larger pharmaceutical companies for commercialization. The only executed license to date is a 2016 territorial agreement with SciClone Pharmaceuticals (Hong Kong) covering China, under which SciClone subsequently invested €2.5M for an equity stake in December 2020. The company has raised approximately €15.5M+ cumulatively across equity rounds (Inveready, CTI Life Sciences Fund, EIC Fund, CDTI Innvierte, FiTalent, family offices IVAMOSA and GESAMO, Capital Cell crowdfunding) and non-dilutive grants (Next Generation EU, Ministry of Science and Innovation of Spain), with the most recent €7M round in March 2024 funding the Phase 2b program and management targeting a multinational out-licensing or commercialization event by 2028.

Customers, in the licensing sense, are enterprise pharmaceutical partners rather than end patients; the company's customer base currently consists of a single Chinese licensee and a network of leading European oncology clinical trial sites (Vall d'Hebron Institute of Oncology, Institut Gustave-Roussy, Centre Léon Bérard, Institut Català d'Oncologia, INCLIVA, Hospital Virgen del Rocío, Institut Paoli-Calmettes). The company employs 1–10 people and is led by co-founder, CEO and Executive Chairman Carles Domènech, with manufacturing secured through a 2024 partnership with AGC Pharma Chemicals for API production.

Short descriptiontext

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Barcelona, Spain, developing first-in-class oral autophagy-inducing small molecules (lead asset: ABTL0812 / IBRILATAZAR) for pancreatic, lung, endometrial, biliary, and pediatric cancers, with a China license to SciClone and a 2028 out-licensing target.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCerdanyola del Vallès, Spain
HQ citystring
Cerdanyola del Vallès
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, autophagy therapeutics, clinical-stage biopharmaceutical, cancer small molecules, orphan drug pipeline
Industry1 code
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Oncology Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical licensing and out-licensing
TypeLicensing Royalties
Description

Pre-revenue clinical stage company with strategy to license developed drugs to larger pharmaceutical or biotechnology companies for commercialization. In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with SciClone Pharmaceuticals (Hong Kong) Development Co. Limited to develop and market the product in China.

abilitypharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1IBRILATAZAR (ABTL0812)
Description

First-in-class fully differentiated oral targeted anticancer compound causing cell death by autophagy (self-digestion). WHO-approved international non-proprietary name for the company's lead drug candidate.

abilitypharma.com
Core offering1 text field

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops first-in-class oral small-molecule anticancer drugs designed to induce cytotoxic autophagy selectively in cancer cells by targeting PPARα and PPARγ nuclear receptors. Its lead asset, ABTL0812 (INN: IBRILATAZAR), is in Phase 2b for metastatic pancreatic cancer and has shown positive Phase 2a results in squamous NSCLC and endometrial cancer. The company monetizes its pipeline through territorial out-licensing deals with larger pharmaceutical partners rather than through direct commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 100% increase in overall survival in sqNSCLC patients (11.3 months to 22.5 months) compared to historical controls
+4 more records
Product overview1 text field

Ability Pharmaceuticals is a clinical-stage Phase 2b biopharmaceutical company developing first-in-class anticancer drugs focused on autophagy as a new therapeutic strategy to induce cell death selectively in cancer cells. The company's core product is ABTL0812 (now named IBRILATAZAR), an oral targeted anticancer compound that induces cytotoxic autophagy. The company is also generating a portfolio of new drug candidates targeting oncological unmet needs.

Product and service2 records
1ABTL0812 / IBRILATAZAR
CategoryDrug candidate (oncology small molecule)
Description

First-in-class oral small-molecule anticancer drug candidate that binds PPARα and PPARγ nuclear receptors, induces ER-stress, and blocks Akt in the PI3K/Akt/mTOR pathway to selectively cause autophagy-mediated cancer cell death. Currently in Phase 2b for metastatic pancreatic cancer with positive Phase 2a results in endometrial cancer and squamous NSCLC; intended for out-licensing to pharmaceutical partners for global or regional commercialization.

2Autophagy-based cancer therapeutics pipeline
CategoryResearch pipeline (oncology drug discovery)
Description

Portfolio of new small-molecule drug candidates built on the company's autophagy-inducing mechanism of action, targeting unmet needs across oncology indications including pancreatic, lung, endometrial, biliary, and pediatric neuroblastoma cancers. The pipeline is licensed to pharmaceutical partners for development and commercialization.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2024-07-16
Description

Partnership for the production of innovative treatment for pancreatic cancer. AGC Pharma Chemicals is consolidating its entry into the process development and manufacturing sector for active pharmaceutical ingredients (APIs) for third parties globally from Spain.

2Dr. Lizcano's group from Autonomous University of Barcelona (UAB)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-11-21
Description

Research consortium formed to study anticancer immunomodulatory effects of ABTL0812 and identify new anticancer immunotherapeutic candidates based on modulation of autophagy. Dr. Lizcano's group previously elucidated ABTL0812's mechanism of action and leads the study on ABTL0812 immunomodulation. Part of €1.5M Next Generation EU funding project.

abilitypharma.com
3SciClone Pharmaceuticals (Hong Kong) Development Co. Limited
Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2016-04-01
Description

Chinese pharmaceutical company that entered as shareholder in December 2020 with €2.5 million investment. Signed territorial license agreement in April 2016 for ABTL0812 to develop and market the product in China.

abilitypharma.com
4Vall d'Hebron Institute of Oncology (VHIO)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading oncology institute in Barcelona that led the Phase 2a clinical study in lung cancer and endometrial cancer. Key clinical trial site for ABTL0812 studies in Spain.

abilitypharma.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading cancer institute in Paris, France. Clinical trial site for Phase 2a study in lung cancer and endometrial cancer.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading cancer research center in Lyon, France. Clinical trial site for Phase 2a study in lung cancer and endometrial cancer.

7Institut Català d'Oncologia (ICO)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Catalan Institute of Oncology with sites in Hospitalet, Badalona, and Girona. Clinical trial site for Phase 2a lung cancer study.

abilitypharma.com
8Hospital Clínico de Valencia (INCLIVA)
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trial site for Phase 2a lung cancer study.

abilitypharma.com
Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trial site for Phase 2a lung cancer study in Seville.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Clinical trial site for Phase 2a lung cancer study in Marseille, France.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Madrid-based clinical-to-commercial oncology biopharmaceutical company developing novel marine-derived small molecule cancer therapeutics. Highly comparable as a Spain-headquartered clinical-stage oncology specialist pursuing licensing-driven commercialization of differentiated mechanisms.

TypeDirect peer
Description

Swedish clinical-stage biotech developing antibody-based therapies for cancer and autoimmune disease, with nadunilimab advancing in pancreatic cancer. Comparable as a European clinical-stage oncology company targeting pancreatic cancer with a differentiated immuno-oncology mechanism and partnership-driven commercialization.

3Targovax ASA
TypeDirect peer
Description

Norwegian clinical-stage immuno-oncology company developing oncolytic virus therapies (TG01) for pancreatic cancer. Comparable as a European clinical-stage oncology company focused on hard-to-treat solid tumors, particularly pancreatic cancer, with a licensing and partnership-oriented commercialization model.

TypeDirect peer
Description

Swedish clinical-stage biotech developing tumor-directed antibody-based immuno-oncology therapeutics. Comparable as a Scandinavian clinical-stage oncology company of similar size and development stage, advancing differentiated immuno-oncology mechanisms toward clinical proof-of-concept.

TypeDirect peer
Description

French clinical-stage biopharmaceutical company developing oncology therapeutics with a focus on difficult-to-treat cancers. Comparable as a European clinical-stage oncology specialist of similar size, focused on innovative mechanisms for solid tumor indications and pursuing strategic partnerships for development.

TypeRegional player
Description

Spanish clinical-stage biotech developing epigenetic therapies for oncology and CNS diseases. Comparable as a Spain-based clinical-stage biotech of similar scale and stage, with a similar capital structure reliant on public grants, EU funding, and institutional VC.

TypeDirect peer
Description

French clinical-stage biopharmaceutical company developing small molecule therapeutics, with historical focus in liver and metabolic diseases and expanding into oncology. Comparable as a European clinical-stage small molecule developer of similar scale pursuing out-licensing and partnership transactions.

TypeDirect peer
Description

Swedish clinical-stage immuno-oncology company developing antibody-based therapeutics for cancer. Comparable as a Scandinavian clinical-stage oncology company of similar headcount and capital base, focused on novel mechanisms and partnership-driven development.

TypeBroad incumbent
Description

Large Danish clinical-to-commercial oncology biotechnology company developing differentiated antibody therapeutics. Comparable as a European oncology biotech founded on differentiated mechanism-of-action science and pursuing broad partnership-based commercialization, though at materially greater scale.

TypeOthers
Description

Dutch CDMO specializing in viral vector and protein production for clinical and commercial biopharmaceuticals. Comparable as a European biopharma ecosystem participant and AGC-adjacent service provider supporting the kind of late-stage manufacturing infrastructure AbilityPharma will rely on for ABTL0812 scale-up.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ability Pharmaceuticals

Oncology Therapeuticsabilitypharma.com

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Barcelona, Spain, developing first-in-class oral autophagy-inducing small molecules (lead asset: ABTL0812 / IBRILATAZAR) for pancreatic, lung, endometrial, biliary, and pediatric cancers, with a China license to SciClone and a 2028 out-licensing target.

What Ability Pharmaceuticals does

Ability Pharmaceuticals (AbilityPharma / ABILITY PHARMACEUTICALS, SA) is a clinical-stage biopharmaceutical company headquartered in Cerdanyola del Vallès (Barcelona), Catalonia, Spain, founded in 2012. It is developing a portfolio of first-in-class small-molecule anticancer drugs that induce cytotoxic autophagy selectively in cancer cells; its lead candidate ABTL0812 (WHO International Nonproprietary Name: IBRILATAZAR) is an oral compound that binds the nuclear receptors PPARα and PPARγ, induces Endoplasmic Reticular Stress, and blocks Akt activation in the PI3K/Akt/mTOR pathway, also converting "cold" tumors into immunogenic "hot" tumors. The asset has Orphan Drug Designations from both the US FDA and the European EMA for pancreatic cancer, biliary cancer, and pediatric neuroblastoma, and is currently in a Phase 2b double-blind placebo-controlled trial in 140 patients with metastatic pancreatic cancer across Spain, USA, France, and Israel, having previously reported positive Phase 2a results in endometrial cancer and squamous non-small cell lung cancer.

The company does not sell commercial products. Its revenue model is out-licensing: AbilityPharma develops drugs to late clinical stage and then licenses territorial or global rights to larger pharmaceutical companies for commercialization. The only executed license to date is a 2016 territorial agreement with SciClone Pharmaceuticals (Hong Kong) covering China, under which SciClone subsequently invested €2.5M for an equity stake in December 2020. The company has raised approximately €15.5M+ cumulatively across equity rounds (Inveready, CTI Life Sciences Fund, EIC Fund, CDTI Innvierte, FiTalent, family offices IVAMOSA and GESAMO, Capital Cell crowdfunding) and non-dilutive grants (Next Generation EU, Ministry of Science and Innovation of Spain), with the most recent €7M round in March 2024 funding the Phase 2b program and management targeting a multinational out-licensing or commercialization event by 2028.

Customers, in the licensing sense, are enterprise pharmaceutical partners rather than end patients; the company's customer base currently consists of a single Chinese licensee and a network of leading European oncology clinical trial sites (Vall d'Hebron Institute of Oncology, Institut Gustave-Roussy, Centre Léon Bérard, Institut Català d'Oncologia, INCLIVA, Hospital Virgen del Rocío, Institut Paoli-Calmettes). The company employs 1–10 people and is led by co-founder, CEO and Executive Chairman Carles Domènech, with manufacturing secured through a 2024 partnership with AGC Pharma Chemicals for API production.

Ability Pharmaceuticals firmographics

Firmographics
Name
Ability Pharmaceuticals
Legal name
ABILITY PHARMACEUTICALS, SA
Website
https://abilitypharma.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
11–50 employees
Short description
Ability Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Barcelona, Spain, developing first-in-class oral autophagy-inducing small molecules (lead asset: ABTL0812 / IBRILATAZAR) for pancreatic, lung, endometrial, biliary, and pediatric cancers, with a China license to SciClone and a 2028 out-licensing target.
Ownership category
akta.pro rank

Ability Pharmaceuticals industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIACAA
Oncology Specialty Pharmaceuticals

Keywords

  • Oncology drug development
  • Autophagy therapeutics
  • Clinical-stage biopharmaceutical
  • Cancer small molecules
  • Orphan drug pipeline

Where Ability Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Cerdanyola del Vallès
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Ability Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Pharmaceutical licensing and out-licensing: Pre-revenue clinical stage company with strategy to license developed drugs to larger pharmaceutical or biotechnology companies for commercialization. In April 2016, AbilityPharma signed a territorial license agreement for ABTL0812 with SciClone Pharmaceuticals (Hong Kong) Development Co. Limited to develop and market the product in China.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Ability Pharmaceuticals product offering

Product offering

Core offering

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops first-in-class oral small-molecule anticancer drugs designed to induce cytotoxic autophagy selectively in cancer cells by targeting PPARα and PPARγ nuclear receptors. Its lead asset, ABTL0812 (INN: IBRILATAZAR), is in Phase 2b for metastatic pancreatic cancer and has shown positive Phase 2a results in squamous NSCLC and endometrial cancer. The company monetizes its pipeline through territorial out-licensing deals with larger pharmaceutical partners rather than through direct commercialization.

Product overview

Ability Pharmaceuticals is a clinical-stage Phase 2b biopharmaceutical company developing first-in-class anticancer drugs focused on autophagy as a new therapeutic strategy to induce cell death selectively in cancer cells. The company's core product is ABTL0812 (now named IBRILATAZAR), an oral targeted anticancer compound that induces cytotoxic autophagy. The company is also generating a portfolio of new drug candidates targeting oncological unmet needs.

Differentiator

Problem solved

Functional benefit

Brands

  • IBRILATAZAR (ABTL0812): First-in-class fully differentiated oral targeted anticancer compound causing cell death by autophagy (self-digestion). WHO-approved international non-proprietary name for the company's lead drug candidate.

Products and services

  • ABTL0812 / IBRILATAZAR First-in-class oral small-molecule anticancer drug candidate that binds PPARα and PPARγ nuclear receptors, induces ER-stress, and blocks Akt in the PI3K/Akt/mTOR pathway to selectively cause autophagy-mediated cancer cell death. Currently in Phase 2b for metastatic pancreatic cancer with positive Phase 2a results in endometrial cancer and squamous NSCLC; intended for out-licensing to pharmaceutical partners for global or regional commercialization.
  • Autophagy-based cancer therapeutics pipeline Portfolio of new small-molecule drug candidates built on the company's autophagy-inducing mechanism of action, targeting unmet needs across oncology indications including pancreatic, lung, endometrial, biliary, and pediatric neuroblastoma cancers. The pipeline is licensed to pharmaceutical partners for development and commercialization.

Quantifiable outcome

  • 100% increase in overall survival in sqNSCLC patients (11.3 months to 22.5 months) compared to historical controls
  • +4 more outcomes

Companies that use Ability Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

Ability Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Ability Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, major and supporting.

  • AGC Pharma ChemicalscoreTechnology or Integration · 16 July 2024Partnership for the production of innovative treatment for pancreatic cancer. AGC Pharma Chemicals is consolidating its entry into the process development and manufacturing sector for active pharmaceutical ingredients (APIs) for third parties globally from Spain.
  • Dr. Lizcano's group from Autonomous University of Barcelona (UAB)coreStrategic or Co-development Partner · 21 November 2022Research consortium formed to study anticancer immunomodulatory effects of ABTL0812 and identify new anticancer immunotherapeutic candidates based on modulation of autophagy. Dr. Lizcano's group previously elucidated ABTL0812's mechanism of action and leads the study on ABTL0812 immunomodulation. Part of €1.5M Next Generation EU funding project.
  • SciClone Pharmaceuticals (Hong Kong) Development Co. LimitedmajorOEM/ Whitelabel/ Licensing Partner · 1 April 2016Chinese pharmaceutical company that entered as shareholder in December 2020 with €2.5 million investment. Signed territorial license agreement in April 2016 for ABTL0812 to develop and market the product in China.
  • Vall d'Hebron Institute of Oncology (VHIO)coreStrategic or Co-development PartnerLeading oncology institute in Barcelona that led the Phase 2a clinical study in lung cancer and endometrial cancer. Key clinical trial site for ABTL0812 studies in Spain.
  • Institut Gustave-RoussycoreStrategic or Co-development PartnerLeading cancer institute in Paris, France. Clinical trial site for Phase 2a study in lung cancer and endometrial cancer.
  • Centre Léon BérardcoreStrategic or Co-development PartnerLeading cancer research center in Lyon, France. Clinical trial site for Phase 2a study in lung cancer and endometrial cancer.
  • Institut Català d'Oncologia (ICO)supportingStrategic or Co-development PartnerCatalan Institute of Oncology with sites in Hospitalet, Badalona, and Girona. Clinical trial site for Phase 2a lung cancer study.
  • Hospital Clínico de Valencia (INCLIVA)supportingStrategic or Co-development PartnerClinical trial site for Phase 2a lung cancer study.
  • Hospital Virgen del RocíosupportingStrategic or Co-development PartnerClinical trial site for Phase 2a lung cancer study in Seville.
  • Institut Paoli-CalmettessupportingStrategic or Co-development PartnerClinical trial site for Phase 2a lung cancer study in Marseille, France.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Ability Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • PharmaMar: Madrid-based clinical-to-commercial oncology biopharmaceutical company developing novel marine-derived small molecule cancer therapeutics. Highly comparable as a Spain-headquartered clinical-stage oncology specialist pursuing licensing-driven commercialization of differentiated mechanisms.
  • Cantargia AB: Swedish clinical-stage biotech developing antibody-based therapies for cancer and autoimmune disease, with nadunilimab advancing in pancreatic cancer. Comparable as a European clinical-stage oncology company targeting pancreatic cancer with a differentiated immuno-oncology mechanism and partnership-driven commercialization.
  • Targovax ASA: Norwegian clinical-stage immuno-oncology company developing oncolytic virus therapies (TG01) for pancreatic cancer. Comparable as a European clinical-stage oncology company focused on hard-to-treat solid tumors, particularly pancreatic cancer, with a licensing and partnership-oriented commercialization model.
  • Alligator Bioscience AB: Swedish clinical-stage biotech developing tumor-directed antibody-based immuno-oncology therapeutics. Comparable as a Scandinavian clinical-stage oncology company of similar size and development stage, advancing differentiated immuno-oncology mechanisms toward clinical proof-of-concept.
  • Onxeo SA: French clinical-stage biopharmaceutical company developing oncology therapeutics with a focus on difficult-to-treat cancers. Comparable as a European clinical-stage oncology specialist of similar size, focused on innovative mechanisms for solid tumor indications and pursuing strategic partnerships for development.
  • Genfit SA: French clinical-stage biopharmaceutical company developing small molecule therapeutics, with historical focus in liver and metabolic diseases and expanding into oncology. Comparable as a European clinical-stage small molecule developer of similar scale pursuing out-licensing and partnership transactions.
  • BioInvent International AB: Swedish clinical-stage immuno-oncology company developing antibody-based therapeutics for cancer. Comparable as a Scandinavian clinical-stage oncology company of similar headcount and capital base, focused on novel mechanisms and partnership-driven development.

Regional players

  • Oryzon Genomics SA: Spanish clinical-stage biotech developing epigenetic therapies for oncology and CNS diseases. Comparable as a Spain-based clinical-stage biotech of similar scale and stage, with a similar capital structure reliant on public grants, EU funding, and institutional VC.

Broad incumbents

  • Genmab A/S: Large Danish clinical-to-commercial oncology biotechnology company developing differentiated antibody therapeutics. Comparable as a European oncology biotech founded on differentiated mechanism-of-action science and pursuing broad partnership-based commercialization, though at materially greater scale.

Others

  • Halix BV: Dutch CDMO specializing in viral vector and protein production for clinical and commercial biopharmaceuticals. Comparable as a European biopharma ecosystem participant and AGC-adjacent service provider supporting the kind of late-stage manufacturing infrastructure AbilityPharma will rely on for ABTL0812 scale-up.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Ability Pharmaceuticals social profiles

Digital presence

Ability Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ability Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Ability Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ability Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ability Pharmaceuticals

What does Ability Pharmaceuticals do?

Ability Pharmaceuticals is a clinical-stage biopharmaceutical company that discovers and develops first-in-class oral small-molecule anticancer drugs designed to induce cytotoxic autophagy selectively in cancer cells by targeting PPARα and PPARγ nuclear receptors. Its lead asset, ABTL0812 (INN: IBRILATAZAR), is in Phase 2b for metastatic pancreatic cancer and has shown positive Phase 2a results in squamous NSCLC and endometrial cancer. The company monetizes its pipeline through territorial out-licensing deals with larger pharmaceutical partners rather than through direct commercialization.

Is Ability Pharmaceuticals a public or private company?

Ability Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Ability Pharmaceuticals founded?

Ability Pharmaceuticals was founded in 2012. It employs 11 to 50 people.

Where is Ability Pharmaceuticals based?

Ability Pharmaceuticals is headquartered in Cerdanyola del Vallès, Spain, in the Europe region.

How does Ability Pharmaceuticals make money?

One revenue line is on record: pharmaceutical licensing and out-licensing.

Who are Ability Pharmaceuticals's main competitors?

Direct peers on record are PharmaMar, Cantargia AB, Targovax ASA, Alligator Bioscience AB, Onxeo SA, Genfit SA and BioInvent International AB. Oryzon Genomics SA is listed as a regional player. Genmab A/S is listed as a broad incumbent. Halix BV is listed as an others.

Does Ability Pharmaceuticals have an API?

No public API is recorded for Ability Pharmaceuticals.

What industry is Ability Pharmaceuticals in?

Ability Pharmaceuticals's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Empresas de Capital Riesgo en EspaAbilityPharma announces a €7M investment from a European-Canadian syndicate of life sciences investors, including CTI Life Sciences Fund, Inveready, the EIC Fund, Fitalent and CDTI InnvierteAbilityPharma secured a €7 million investment from a syndicate of investors including CTI Life Sciences Fund, Inveready, and the EIC Fund to finance its Phase 2b clinical study for pancreatic cancer treatment ABTL0812. The funding supports an ongoing double-blind trial across hospitals in Spain, the US, France, and Israel, with efficacy results expected by year-end. Success in these trials is intended to enable further development or licensing of the molecule to reach patients by 2028.AbilitypharmaAbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic CancerAbilityPharma secured a €7 million financing round from a syndicate of investors, including CTI Life Sciences Fund and the EIC Fund, to fully finance its Phase 2b clinical study of ABTL0812 for metastatic pancreatic cancer. The company is currently completing this trial across hospitals in Spain, the US, France, and Israel, with efficacy results expected by year-end. Successful outcomes could enable further development or licensing of the molecule, aiming for patient availability by 2028.PR NewswireAbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic CancerAbility Pharmaceuticals, SA (AbilityPharma) announced a €7 million investment to advance its clinical development of the autophagy inducer ABTL0812 for metastatic pancreatic cancer. The financing round was supported by a European-Canadian syndicate of life sciences investors including CTI Life Sciences Fund, Inveready, and the EIC Fund. AbilityPharma aims to demonstrate the efficacy of ABTL0812 in comparison to standard treatments and targets patient availability by 2028.WebcapitalriesgoAbilityPharma cierra una ronda de €7M liderada por CTI Life Sciences Fund, Inveready y EIC Fund. Participan CDTI Innvierte, FiTalent, fundadores y CapitalCellAbilityPharma has secured a €7 million investment round led by CTI Life Sciences Fund, Inveready, and the EIC Fund to fully finance its Phase 2b clinical trial for the pancreatic cancer drug ABTL0812. The company expects efficacy results from the multinational study in Spain, the United States, France, and Israel by the end of 2024, which could facilitate further development or licensing opportunities. This funding builds on previous support from Spanish government programs and aims to accelerate the treatment's path toward potential patient availability by 2028.PlantaDoceAbility Pharmaceuticals reordena su consejo con la salida de InvereadyInveready, a venture capital firm, has exited Ability Pharmaceuticals' board, where it was represented by Roger Piqué. The biotech closed a €1.2M crowdfunding round led by Capital Cell, with 377 investors. Ability plans to use the funds for its cancer drug ABTL0812, which is in Phase II trials.Diari ARAEmprendre contra el càncerFive Catalan cancer startups are developing personalized treatments, with 38% of CataloniaBio's biotech members focused on oncology. They face funding gaps and licensing deals, such as Ability Pharma's €17.5M agreement with SciClone. The sector aims for European regulatory approval and broader market access.PR NewswireAbility Pharmaceuticals Announces Orphan Drug Designation in the US for ABTL0812 in Pancreatic CancerAbility Pharmaceuticals announced receipt of Orphan Drug Designation from the US FDA for ABTL0812 in pancreatic cancer, following similar designations for pediatric neuroblastoma granted by both FDA and EMA in 2015. In preclinical studies, the drug demonstrated synergistic effects when combined with standard chemotherapy agents, with tumor regression induction without added toxicity. ABTL0812 is currently in Phase 2 trials for endometrial and squamous lung cancer at two Barcelona-based oncology institutes.PR NewswireAbility Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First-Line Therapy in Patients with Endometrial or Squamous Lung CancerAbilityPharma announced the initiation of a Phase 2 clinical trial evaluating its targeted drug candidate ABTL0812 as first-line therapy combined with paclitaxel and carboplatin in 80 patients with advanced or recurrent endometrial cancer or squamous lung cancer. The trial is being led by Vall d'Hebron Institute of Oncology and Catalan Institute of Oncology in Barcelona, with additional sites planned in France and Spain over the next six months. The company cited positive safety data from Phase 1b and high efficacy in preclinical models as rationale for advancing the combination therapy study.